Nanobiotix S.A.
NBTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001760854
No open-market purchases or sales by Nanobiotix S.A. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $218.4M in total; no superinvestor holds it.
Other share classesNNBXF
13F holders, Q2 2021
Institutional positions in Nanobiotix S.A. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- 0 vs. Q1 2021
- Shares held
- 4.85M
- −14.8K (−0.3%) vs. Q1 2021
- Total value
- $66.9M
- −$6.31M (−8.6%) vs. Q1 2021
- New holders
- 0
- 1 more added
- Sold out
- 0
- 2 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NBTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $218.4M |
| Q1 2026 | 15 | $175.9M |
| Q4 2025 | 14 | $131.8M |
| Q3 2025 | 11 | $106.6M |
| Q2 2025 | 10 | $25.6M |
| Q1 2025 | 12 | $20.6M |
| Q4 2024 | 18 | $17.4M |
| Q3 2024 | 10 | $36.9M |
| Q2 2024 | 12 | $46.5M |
| Q1 2024 | 12 | $59.7M |
| Q4 2023 | 12 | $67.5M |
| Q3 2023 | 9 | $39.1M |
| Q2 2023 | 5 | $17.7M |
| Q1 2023 | 4 | $12.4M |
| Q4 2022 | 5 | $12.2M |
| Q3 2022 | 5 | $12.2M |
| Q2 2022 | 6 | $13.3M |
| Q1 2022 | 6 | $26.0M |
| Q4 2021 | 7 | $28.8M |
| Q3 2021 | 9 | $46.5M |
| Q2 2021 | 10 | $66.9M |
| Q1 2021 | 10 | $73.2M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Nanobiotix S.A.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baillie Gifford & Co | 1,400,000 | $19.3M | 0.01% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 1,059,800 | $14.6M | 0.19% | 00.0% | Unchanged |
| Artal Group S.A. | 1,000,000 | $13.8M | 0.31% | 00.0% | Unchanged |
| Tybourne Capital Management (HK) Ltd | 750,000 | $10.3M | 0.22% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 500,000 | $6.89M | 0.07% | 00.0% | Unchanged |
| Woodline Partners LP | 59,994 | $827.0K | 0.02% | −4,520−7.0% | Reduced |
| UBS Group AG | 59,791 | $824.0K | 0.00% | −10,391−14.8% | Reduced |
| Millennium Management LLC | 22,233 | $306.0K | 0.00% | +151+0.7% | Added |
| Morgan Stanley | 300 | $4.00K | 0.00% | 00.0% | Unchanged |
| Activest Wealth Management | 283 | $4.00K | 0.00% | 00.0% | Unchanged |